Genprex, Inc. — Investor Relations & Filings
Filings indexed
465
across all filing types
Latest filing
2026-04-30
Regulatory Filings
Country
US
United States of America
Listing
US
GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapeutic options for large patient populations. Its oncology pipeline includes clinical-stage programs for lung cancer, such as the Acclaim-3 trial in small cell lung cancer (SCLC) and other programs for non-small cell lung cancer (NSCLC). In addition to its cancer programs, Genprex is developing gene therapies for diabetes. The company utilizes a proprietary, non-viral nanoparticle delivery system to systemically deliver therapeutic genes.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-30 | English | |
| 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-28 | English | |
| 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-21 | English | |
| 4 - GENPREX, INC. (0001595248) (Filer) | 2026-02-27 | English | |
| 4 - GENPREX, INC. (0001595248) (Filer) | 2026-02-27 | English | |
| 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-02-23 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
12 filings
| |||||
| 39079012 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-30 | English | ||
| 37966942 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-28 | English | ||
| 34744649 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-04-21 | English | ||
| 32894757 | 4 - GENPREX, INC. (0001595248) (Filer) | 2026-02-27 | English | ||
| 32894758 | 4 - GENPREX, INC. (0001595248) (Filer) | 2026-02-27 | English | ||
| 32827314 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-02-23 | English | ||
| 30796874 | SCHEDULE 13G Filing | 2026-02-11 | English | ||
| 19423450 | 8-K - Genprex, Inc. (0001595248) (Filer) | 2026-02-10 | English | ||
| 12735587 | FORM 8-K | 2026-01-09 | English | ||
| 12735588 | FORM S-8 | 2026-01-09 | English | ||
| 12735590 | FORM 8-K | 2026-01-07 | English | ||
| 12735589 | FORM 8-K | 2026-01-06 | English | ||
|
2025
3 filings
| |||||
| 12735591 | FORM 4 | 2025-12-23 | English | ||
| 12735592 | FORM 4 | 2025-12-23 | English | ||
| 12735593 | FORM 4 | 2025-12-23 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Ovation Science Inc.
Develops and licenses patented Invisicare® technology for e…
|
OVAT | CA | Professional, scientific and te… |
|
OXFORD BIODYNAMICS PLC
Develops and commercializes precision medicine tests for on…
|
OBD | GB | Professional, scientific and te… |
|
Oxurion NV
Acquires majority stakes in European pharmaceutical subcont…
|
OXUR | BE | Professional, scientific and te… |
|
PACIFIC EDGE LIMITED
Develops non-invasive molecular tests for bladder cancer de…
|
PEB | NZ | Professional, scientific and te… |
|
PARADIGM BIOPHARMACEUTICALS LIMITED..
Repurposing PPS for osteoarthritis and rare inflammatory di…
|
PAR | AU | Professional, scientific and te… |
|
Pasithea Therapeutics Corp.
Develops treatments for central nervous system disorders, R…
|
KTTA | US | Professional, scientific and te… |
|
Passage BIO, Inc.
A clinical-stage genetic medicines company developing thera…
|
PASG | US | Professional, scientific and te… |
|
PATRYS LIMITED
Develops Deoxymab antibody therapies targeting DNA repair m…
|
PAB | AU | Professional, scientific and te… |
|
PAVmed Inc.
A diversified medical technology company developing devices…
|
PAVM | US | Professional, scientific and te… |
|
PegBio Co., Ltd.
Specializes in discovering and developing innovative therap…
|
2565 | HK | Professional, scientific and te… |
Genprex, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35333/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35333 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35333 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35333 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35333}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Genprex, Inc. (id: 35333)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.